MeSH term
Frequency | Condition_Probility | Humans | 67 | 0.0 |
3T3 Cells | 2 | 0.0 |
Animals | 12 | 0.0 |
Mice | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 49 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
English Abstract | 2 | 0.0 |
Macular Degeneration/*genetics | 8 | 16.0 |
Mutation | 5 | 0.0 |
Phenotype | 4 | 0.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinase-3/genetics | 6 | 42.0 |
Eye Proteins/genetics | 2 | 4.0 |
Linkage (Genetics) | 2 | 0.0 |
DNA Methylation | 3 | 0.0 |
Female | 33 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Polymerase Chain Reaction | 16 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Adult | 25 | 0.0 |
Aged | 23 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
*DNA Methylation | 24 | 3.0 |
Disease Progression | 3 | 0.0 |
Gene Expression Profiling | 4 | 0.0 |
Middle Aged | 26 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Gene Silencing | 3 | 0.0 |
Genes, Tumor Suppressor | 3 | 0.0 |
Genetic Markers | 2 | 0.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Down-Regulation | 4 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Comparative Study | 7 | 0.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Male | 30 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Up-Regulation | 2 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Pedigree | 9 | 0.0 |
Visual Acuity | 2 | 1.0 |
Base Sequence | 15 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Rats | 2 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
CpG Islands | 7 | 2.0 |
DNA Modification Methylases/antagonists & inhibitors | 4 | 15.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Protein p16/genetics | 3 | 3.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
Genes, p16 | 3 | 3.0 |
Haplotypes | 4 | 0.0 |
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics | 3 | 2.0 |
p14ARF Protein/genetics | 4 | 19.0 |
Exons | 4 | 0.0 |
Introns | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Tissue Inhibitor of Metalloproteinase-3/*genetics | 4 | 100.0 |
Cloning, Molecular | 4 | 0.0 |
Metalloendopeptidases/antagonists & inhibitors | 3 | 13.0 |
Tissue Inhibitor of Metalloproteinases/*genetics | 3 | 75.0 |
Chromosomes, Human, Pair 22 | 3 | 1.0 |
DNA Mutational Analysis | 4 | 0.0 |
DNA | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Gene Expression Regulation, Developmental/*genetics | 2 | 2.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Adenoma/genetics | 2 | 4.0 |
Colorectal Neoplasms/*genetics/pathology | 2 | 2.0 |
*CpG Islands | 2 | 2.0 |
Adolescent | 7 | 0.0 |
*Fundus Oculi | 4 | 50.0 |
*Point Mutation | 4 | 0.0 |
Lod Score | 2 | 0.0 |
Proteins/*genetics | 7 | 0.0 |
Tissue Inhibitor of Metalloproteinase-3 | 12 | 80.0 |
Retinal Diseases/*genetics | 2 | 6.0 |
Age of Onset | 3 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 6 | 0.0 |
CpG Islands/*genetics | 6 | 6.0 |
Ependymoma/*genetics | 2 | 18.0 |
Proteins/genetics | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
DNA Primers | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Extracellular Matrix/metabolism | 2 | 1.0 |
Metalloendopeptidases/*antagonists & inhibitors | 2 | 7.0 |
Prognosis | 4 | 0.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Retina/*metabolism | 2 | 3.0 |
Time Factors | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Azacitidine/*analogs & derivatives/pharmacology | 2 | 2.0 |
Caspases/genetics | 2 | 8.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
Infant | 2 | 0.0 |
Sulfites/pharmacology | 2 | 6.0 |
Chronic Disease | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Adenoma/*genetics/pathology | 2 | 7.0 |
